Plaquenil: Effective Management of Autoimmune Conditions
Plaquenil
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $4.00 | $100.00 $80.00 (20%) | 🛒 Add to cart |
| 30 | $3.67 | $150.00 $110.00 (27%) | 🛒 Add to cart |
| 60 | $3.50 | $300.00 $210.00 (30%) | 🛒 Add to cart |
| 90 | $3.33 | $450.00 $300.00 (33%) | 🛒 Add to cart |
| 120 | $2.92 | $600.00 $350.00 (42%) | 🛒 Add to cart |
| 180 | $2.78 | $900.00 $500.00 (44%) | 🛒 Add to cart |
| 270 | $2.59 | $1350.00 $700.00 (48%) | 🛒 Add to cart |
| 360 | $2.39
Best per pill | $1800.00 $860.00 (52%) | 🛒 Add to cart |
| Product dosage: 400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.00 | $70.00 (0%) | 🛒 Add to cart |
| 20 | $6.00 | $140.00 $120.00 (14%) | 🛒 Add to cart |
| 30 | $5.67 | $210.00 $170.00 (19%) | 🛒 Add to cart |
| 60 | $5.33 | $420.00 $320.00 (24%) | 🛒 Add to cart |
| 90 | $5.00 | $630.00 $450.00 (29%) | 🛒 Add to cart |
| 120 | $4.58 | $840.00 $550.00 (35%) | 🛒 Add to cart |
| 180 | $4.44 | $1260.00 $800.00 (37%) | 🛒 Add to cart |
| 270 | $4.26 | $1890.00 $1150.00 (39%) | 🛒 Add to cart |
| 360 | $4.03
Best per pill | $2520.00 $1450.00 (42%) | 🛒 Add to cart |
Plaquenil (hydroxychloroquine sulfate) is a disease-modifying antirheumatic drug (DMARD) widely prescribed for the management of chronic autoimmune disorders. As an immunomodulatory agent, it works by altering immune system activity to reduce inflammation and prevent disease progression. This medication is a cornerstone in the long-term treatment strategy for conditions like rheumatoid arthritis and lupus erythematosus, offering patients sustained symptomatic relief and improved quality of life. Its well-established safety profile and oral administration make it a preferred first-line option in many clinical guidelines.
Features
- Active ingredient: Hydroxychloroquine sulfate
- Available in 200mg oral tablets
- Prescription-only medication
- Manufactured under strict pharmaceutical standards
- Bioequivalent to brand-name formulations
- Long half-life allowing for once or twice daily dosing
Benefits
- Reduces joint pain, swelling, and morning stiffness in rheumatoid arthritis
- Decreases frequency and severity of lupus flares
- Helps prevent long-term joint damage and deformity
- Improves skin manifestations in cutaneous lupus
- May reduce systemic inflammation markers
- Supports maintenance of remission in autoimmune conditions
Common use
Plaquenil is primarily indicated for the treatment of rheumatoid arthritis, systemic lupus erythematosus, and discoid lupus erythematosus. It is also used off-label for other autoimmune conditions including Sjögren’s syndrome, palindromic rheumatism, and certain dermatological conditions. The medication is typically prescribed as part of a comprehensive treatment plan that may include other DMARDs, NSAIDs, or biologic agents depending on disease severity and patient response.
Dosage and direction
The recommended dosage is based on ideal body weight and specific condition being treated. For adults, the usual initial dose is 400-600mg daily (2-3 tablets), often divided into two doses. After achieving optimal response, the dose is typically reduced to a maintenance level of 200-400mg daily. Tablets should be taken with food or milk to minimize gastrointestinal discomfort. Regular ophthalmologic examinations are required due to potential retinal toxicity with long-term use.
Precautions
Patients should undergo baseline ophthalmologic examination within the first year of treatment and annually thereafter. Renal and hepatic function should be monitored periodically. Use with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to hemolysis risk. May exacerbate psoriasis and porphyria. Caution advised in elderly patients and those with pre-existing retinal disease or hepatic impairment.
Contraindications
Hypersensitivity to hydroxychloroquine, 4-aminoquinoline compounds, or any component of the formulation. Contraindicated in patients with pre-existing macular changes or visual field defects. Not recommended in patients with known porphyria. Avoid use in children except for juvenile idiopathic arthritis under specialist supervision.
Possible side effects
Common reactions include gastrointestinal disturbances (nausea, diarrhea, abdominal cramps), headache, and skin eruptions. Ocular effects may include accommodation difficulties, corneal deposits, and rarely, irreversible retinopathy. Less frequent adverse effects include neuromyopathy, cardiomyopathy, and blood dyscrasias. Most side effects are dose-related and often reversible with dosage reduction or discontinuation.
Drug interaction
Plaquenil may enhance the effects of digoxin and insulin. Concomitant use with other hepatotoxic drugs may increase risk of liver damage. Antacids and kaolin may reduce absorption. May increase risk of QT prolongation when used with other QT-prolonging agents. Caution with concomitant use of methotrexate or other DMARDs due to potential additive immunosuppressive effects.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent therapeutic levels. Contact your healthcare provider if multiple doses are missed for guidance on resumption.
Overdose
Symptoms may include headache, visual disturbances, cardiovascular collapse, seizures, and hypokalemia. Management involves immediate gastric lavage and symptomatic treatment. Cardiorespiratory support may be necessary. Serum potassium levels should be monitored as hypokalemia may occur secondary to intracellular shifting. There is no specific antidote.
Storage
Store at room temperature (15-30°C/59-86°F) in original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use if tablets show signs of discoloration or deterioration. Properly dispose of expired medication according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting or changing any treatment regimen. Individual response to medication may vary. Proper diagnosis and monitoring by a physician are essential for safe and effective use.
Reviews
Clinical studies demonstrate Plaquenil’s efficacy in maintaining disease control with favorable long-term safety data. Many patients report significant improvement in quality of life measures and functional capacity. Ophthalmologic monitoring remains crucial for risk mitigation. The medication continues to be a fundamental component in autoimmune disease management protocols worldwide.